For research and education only · Not reviewed by a medical professional · Disclaimer

Peptide encyclopedia/ Matrixyl
Illustration for Matrixyl

THE PEPSRADAR ENCYCLOPEDIA

Matrixyl

Topical skin-formulation research

Cosmetic ingredients · Sources checked 2026-10-04

Read the studies ↓

Matrixyl · KEY FACTS

Content updated · how dates work

Saved peptides

What is Matrixyl?

The Matrixyl ingredient covered here is palmitoylated KTTKS, also known as palmitoyl pentapeptide-4. A split-face study compared a moisturizer containing this ingredient with its base formulation.

Biological role or research focus

Topical skin-formulation research.

The result applies to this formulation and cosmetic follow-up. It does not establish an injection treatment or verify every product using the Matrixyl name.

Role reference: Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin. · 2005 ↗

Names you may encounter

Palmitoyl pentapeptide-4 · Pal-KTTKS · Palmitoyl pentapeptide-3

Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.

Class / identity
Palmitoylated KTTKS cosmetic peptide
Research focus
Topical skin-formulation research
Featured evidence
Human randomized cosmetic trial
Source check
October 4, 2026

Source: Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin. · 2005 ↗

Quick answers

Is Matrixyl FDA approved?
No. No FDA-approved drug contains Matrixyl. Source ↗
Is Matrixyl safe?
Matrixyl (palmitoyl pentapeptide-4) is a cosmetic ingredient. A split-face trial reported it was well tolerated by skin, but finished products vary and long-term skin effects are unstudied. Human safety data: trials only. The Risks & interactions section below lists what is known. Read the risks ↓
Is Matrixyl banned in sport?
It is not named on the 2026 World Anti-Doping Agency (WADA) Prohibited List. Athletes should still check with their sport’s anti-doping body. Source ↗

What does the evidence show?

Evidence map

Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.

1 Human research
StudyTypePopulation / model
Pal-KTTKS split-face trial (2005)Human randomized cosmetic trial93 women aged 35–55.

Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.

Human randomized cosmetic trial · 2005

Pal-KTTKS split-face trial

What did this publication test, and what did it find?

Population / model
93 women aged 35–55.
Study design
Twelve-week randomized double-blind split-face comparison of moisturizer with and without pal-KTTKS.
Main finding
Wrinkle and fine-line grading favored the peptide-containing formulation, which was reported as well tolerated.
Limits & context
The result applies to this formulation and cosmetic follow-up. It does not establish an injection treatment or verify every product using the Matrixyl name.

Source: Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin. · 2005 ↗

Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.

Registered human trials

No study naming Matrixyl as an intervention was found on ClinicalTrials.gov when we last checked (November 16, 2026). That means no registered human trial, not proof that none has ever been done elsewhere.

Further reading · 4 additional publication links

Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.

Synergistic Effects of Injectable Platelet-Rich Fibrin and Bioactive Peptides on Dermal Fibroblast Viability and Extracellular Matrix Gene Expression: An In Vitro Study. ↗
Molecules (Basel, Switzerland) · 2025 Aug 19 · Journal Article
Read available full text ↗

Self-Assembly and Wound Healing Activity of Biomimetic Cycloalkane-Based Lipopeptides. ↗
ACS applied materials & interfaces · 2024 Oct 30 · Journal Article, Research Support, Non-U.S. Gov't
Read available full text ↗

Boosting Cosmeceutical Peptides: Coupling Imidazolium-Based Ionic Liquids to Pentapeptide-4 Originates New Leads with Antimicrobial and Collagenesis-Inducing Activities. ↗
Microbiology spectrum · 2022 Aug 31 · Journal Article, Research Support, Non-U.S. Gov't
Read available full text ↗

Matrixyl Patch vs Matrixyl Cream: A Comparative In Vivo Investigation of Matrixyl (MTI) Effect on Wound Healing. ↗
ACS omega · 2022 Jul 19 · Journal Article
Read available full text ↗

Repeat this PubMed search ↗
Search additional PubMed records ↗

Risks & interactions

Matrixyl (palmitoyl pentapeptide-4) is a cosmetic ingredient. A split-face trial reported it was well tolerated by skin, but finished products vary and long-term skin effects are unstudied.

Human safety data: Trials only

Human evidence is mainly a 12-week split-face cosmetic trial in 93 women, which reported good skin tolerance. Irritation or allergy from finished products with different bases and strengths has not been systematically studied.

It isn't approved, so there is no official list of who should avoid it, and its human studies are too small to show who is most at risk. No condition is tagged, but that does not make it safe for anyone. If a condition applies to you, talk to a doctor or pharmacist first.

Who should not use it

There is no official list, because it has never been approved as a medicine. That is not a sign it is safe for anyone: its risks have not been studied enough to know who is most at risk.

Summarized from published studies with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: Topical palmitoyl pentapeptide in photoaged facial skin (2005) ↗

Safety & what remains unknown

Finished products may have different concentrations, bases, and irritants; ingredient evidence alone cannot establish their tolerability.

Source: Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin. · 2005 ↗

Evidence boundaries

The result applies to this formulation and cosmetic follow-up. It does not establish an injection treatment or verify every product using the Matrixyl name.

Source: Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin. · 2005 ↗

Regulatory status

U.S. FDA approval
Not approved
No FDA-approved drug containing this substance found in Drugs@FDA (openFDA data updated 2026-10-07). source
FDA compounding (503A bulk list)
Not on FDA’s compounding lists
Not found on FDA's 503A category 1, 2 or 3 lists (updated May 14, 2026) or the category 2 safety-risk page (updated April 22, 2026). source
World Anti-Doping Agency (2026)
Not on the WADA Prohibited List
Not named. It is a cosmetic ingredient; WADA's S0 catch-all addresses pharmacological substances, and its application to topical cosmetic ingredients was not determined. source

Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.

This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.

Research context & identity

Matrixyl 3000 is a different ingredient combination. A brand-family name does not identify one universal peptide or formulation.

Source: Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin. · 2005 ↗

New editorial updates

Loading approved updates…

New source discoveries

Links appear automatically. Unreviewed discoveries are not verified medical findings.

Loading recent discoveries…

Explore the latest source feed →

Sources & supplier listings

Listings are grouped by the vendor’s stated identity. Blends and modified derivatives are labeled separately. Inclusion is not a quality assessment or an endorsement.

No verified matching catalog listing yet

We have not added a supplier for this profile. Missing products and coded listings are not filled with guesses.

Biology & proposed mechanism

The publication evaluated a peptide-containing topical formulation through skin appearance. Proposed matrix signaling should be distinguished from the measured cosmetic outcome.

Source: Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin. · 2005 ↗

Questions worth asking

  • Is Matrixyl 3000 the same as this pal-KTTKS ingredient?
  • What material, population, and route were actually studied?
  • The result applies to this formulation and cosmetic follow-up. It does not establish an injection treatment or verify every product using the Matrixyl name.
  • What adverse effects, uncertainty, and conflicts of interest does the original source report?

Frequently asked questions

Is Matrixyl 3000 the same as this pal-KTTKS ingredient?

No. The name covers a different ingredient combination, so its identity and evidence need separate review.

Source: Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin. · 2005 ↗

Does the publication verify a supplier’s product?

No. The tested material and a commercial listing need separate identity and batch checks. A research-use disclaimer does not establish clinical suitability.

Source: Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin. · 2005 ↗

References & editorial record

Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.

For research and education only. This page does not provide medical advice, diagnosis, or treatment. Research-only listings are not instructions for human use.

See something wrong on this page? Report a mistake · Corrections